OncoMatch/Clinical Trials/NCT07489534
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Is NCT07489534 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PD-1Ab21-BCMA CAR-T cell immunotherapy for multiple myeloma.
Treatment: PD-1Ab21-BCMA CAR-T cell immunotherapy — The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal dysfunction.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: clinical first-line treatment
received ≥ 2 courses of clinical first-line treatment, evaluated efficacy above PR
Lab requirements
Blood counts
WBC≥1×10^9/L, LY≥0.3×10^9/L, PT:INR<1.7 or PT prolonged by<4s compared to normal value
Kidney function
Diagnosed with multiple myeloma accompanied by renal dysfunction
Liver function
ALT and AST ≤ 2.5 ULN; Serum total bilirubin ≤ 2.0mg/dL (34.2 μmol/L)
WBC≥1×10^9/L，LY≥0.3×10^9/L，ALT and AST ≤ 2.5 ULN; Serum total bilirubin ≤ 2.0mg/dL (34.2 μmol/L); PT:INR<1.7 or PT prolonged by<4s compared to normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify